Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Immunotherapies in Lung Cancer, Part 2: Dr. Brahmer on Ipilumumab, Anti-PD1, Anticancer Viruses, and Talactoferrin
Author
Howard (Jack) West, MD

Here's the second presentation from our program on "Immunotherapies for Lung Cancer: Can We Deliver on the Promise?".  Our first part was by Dr. Ramaswamy Govindan from Washington University in St. Louis; he was followed by Dr. Julie Brahmer, from Johns Hopkins University, who covered a wide range of immunotherapy concepts: the anti-CTLA4 antibody ipilimumab, or Yervoy; the exciting new approach of anti-PD1 therapy as was more fully presented at ASCO, new work on anticancer vaccine approaches, and discussion of talactoferrin and the past and ongoing trials with it.  

Below you'll find the audio and video versions of the podcast, along with transcript and figures.

Brahmer Immunotherapies for LC Part 2 Audio Podcast

Brahmer Immunotherapies for LC Part 2 Transcript

Brahmer Immunotherapies in LC Part 2 Figs

We'll close out this program with the question and answer session that followed the two presentations.  Look for that soon.

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
Image
Videoteca de Cáncer de Pulmon - 2025
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.